COMMUNIQUÉS West-GlobeNewswire

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05/05/2026
RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic [...]
EPIK Biosciences Launches to Pioneer Ketamine-Powered Psychedelic Therapies to Transform Treatment of Mental Health, Pain, and Addiction
05/05/2026
Advancing synergistic combination medicines, non-opioid solutions for chronic pain, neuropsychiatric disorders, and substance use disorders using patient-friendly delivery methods. AUSTIN, Texas, May 05, 2026 (GLOBE [...]
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
05/05/2026
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today [...]
STERIS Announces Dividend of $0.63 per share
05/05/2026
DUBLIN, IRELAND, May 05, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on [...]
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
05/05/2026
– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) – – Additional data from VIRAGE Phase 2b clinical trial of [...]
FDA Expands Market Access, Authorizes New ENDS Products
05/05/2026
White Oak, Md., May 05, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) today authorized the marketing of four Glas electronic nicotine delivery systems (ENDS) through the premarket tobacco product [...]
Pacira BioSciences Mails Letter to Stockholders
05/05/2026
Details Success of Pacira’s 5x30 Strategy and Solid First Quarter 2026 Results Reiterates Board’s Unanimous Recommendation that Stockholders Vote “FOR” the Election of Pacira’s Highly Qualified Nominees on the BLUE [...]
Sienna Reports First Quarter 2026 Financial Results and Continues Platform Expansion
05/05/2026
MARKHAM, Ontario, May 05, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced its financial results for the three months ended March 31, 2026. Highlights Average [...]
Cytokinetics Announces Proposed Public Offering of Common Stock
05/05/2026
SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $650 million of shares of its [...]
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
05/05/2026
MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today [...]
Iridex to Report First Quarter 2026 Financial Results on May 19, 2026
05/05/2026
MOUNTAIN VIEW, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the [...]
Amwell® Announces Results for First Quarter 2026
05/05/2026
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results for the first [...]
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
05/05/2026
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated [...]
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
05/05/2026
FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib doublet data at Phase [...]
InnovAge Announces Financial Results for the Fiscal Third Quarter Ended March 31, 2026
05/05/2026
DENVER, May 05, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible [...]
Standard BioTools Reports First Quarter 2026 Financial Results
05/05/2026
BOSTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026. Recent Highlights: [...]
Supernus Announces First Quarter 2026 Financial Results
05/05/2026
Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last year. Combined revenues of the Company's four growth products increased to $149.1 million in the first quarter [...]
LeMaitre Q1 2026 Financial Results
05/05/2026
BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2026 results, announced a quarterly dividend of $0.25 [...]
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
05/05/2026
Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), [...]

Pages